- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
MBI extends Mallinckrodt's FS069 rights
Molecular Biosystems of San Diego has extended Mallinckrodt Medical'srights to its FS069 ultrasound contrast agent to Europe, Russia,Africa, and India. In exchange for the new rights, Mallinckrodtof St. Louis will pay MBI fees of up to $12.9 million,
Molecular Biosystems of San Diego has extended Mallinckrodt Medical's
rights to its FS069 ultrasound contrast agent to Europe, Russia,
Africa, and India. In exchange for the new rights, Mallinckrodt
of St. Louis will pay MBI fees of up to $12.9 million, plus 40%
of product sales for royalties and manufacturing. The companies
filed a premarket approval application for U.S. marketing of FS069,
a second-generation contrast agent, earlier this year. They plan
to file for European approval in early 1997.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.
